NCT02490436

Novel Treatment Option for Neuropathic Pain

A Randomized, Cross-over, Placebo-controlled, Double-blind, Single-center, Phase II Study of Cetuximab in Patients With Treatment-refractory, Non-malignant Severe Chronic Neuropathic Pain

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Sorlandet Hospital HF · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether the EGFR-inhibitor cetuximab is better than placebo for the treatment of neuropathic pain.

Conditions

• Neuralgia
• Complex Regional Pain Syndromes

Interventions

Type	Name	Description
DRUG	Cetuximab	Randomized cross-over between cetuximab and placebo
DRUG	Placebo	Randomized cross-over between cetuximab and placebo

Timeline

• Start date: 2015-10-01
• Primary completion: 2016-10-01
• Completion: 2016-10-01
• First posted: 2015-07-03
• Last updated: 2016-11-08

Locations

1 site across 1 country: Norway